Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011 : A study in the United States, Canada, and Germany using retrospective real-world databases
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society..
BACKGROUND: This study aimed to describe treatment patterns and overall survival (OS) in patients with advanced non-small cell lung cancer (aNSCLC) in three countries between 2011 and 2020.
METHODS: Three databases (US, Canada, Germany) were used to identify incident aNSCLC patients. OS was assessed from the date of incident aNSCLC diagnosis and, for patients who received at least a first line of therapy (1LOT), from the date of 1LOT initiation. In multivariable analyses, we analyzed the influence of index year and type of prescribed treatment on OS.
FINDINGS: We included 51,318 patients with an incident aNSCLC diagnosis. The percentage of patients treated with a 1LOT differed substantially between countries, whereas the number of patients receiving immunotherapies/targeted treatments increased over time in all three countries. Median OS from the date of incident diagnosis was 9.9 months in the United States vs. 4.1 months in Canada. When measured from the start of 1LOT, patients had a median OS of 10.7 months in the United States, 10.9 months in Canada, and 10.9 months in Germany. OS from the start of 1LOT improved in all three countries from 2011 to 2020 by approximately 3 to 4 months.
CONCLUSIONS: Observed continuous improvement in OS among patients receiving at least a 1LOT from 2011 to 2020 was likely driven by improved care and changes in the treatment landscape. The difference in the proportion of patients receiving a 1LOT in the observed countries requires further investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Cancer - 130(2024), 4 vom: 15. Feb., Seite 530-540 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Griesinger, Frank [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carcinoma |
|---|
| Anmerkungen: |
Date Completed 09.02.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.35094 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364257237 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364257237 | ||
| 003 | DE-627 | ||
| 005 | 20240312233330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.35094 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM364257237 | ||
| 035 | |a (NLM)37933916 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Griesinger, Frank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011 |b A study in the United States, Canada, and Germany using retrospective real-world databases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. | ||
| 520 | |a BACKGROUND: This study aimed to describe treatment patterns and overall survival (OS) in patients with advanced non-small cell lung cancer (aNSCLC) in three countries between 2011 and 2020 | ||
| 520 | |a METHODS: Three databases (US, Canada, Germany) were used to identify incident aNSCLC patients. OS was assessed from the date of incident aNSCLC diagnosis and, for patients who received at least a first line of therapy (1LOT), from the date of 1LOT initiation. In multivariable analyses, we analyzed the influence of index year and type of prescribed treatment on OS | ||
| 520 | |a FINDINGS: We included 51,318 patients with an incident aNSCLC diagnosis. The percentage of patients treated with a 1LOT differed substantially between countries, whereas the number of patients receiving immunotherapies/targeted treatments increased over time in all three countries. Median OS from the date of incident diagnosis was 9.9 months in the United States vs. 4.1 months in Canada. When measured from the start of 1LOT, patients had a median OS of 10.7 months in the United States, 10.9 months in Canada, and 10.9 months in Germany. OS from the start of 1LOT improved in all three countries from 2011 to 2020 by approximately 3 to 4 months | ||
| 520 | |a CONCLUSIONS: Observed continuous improvement in OS among patients receiving at least a 1LOT from 2011 to 2020 was likely driven by improved care and changes in the treatment landscape. The difference in the proportion of patients receiving a 1LOT in the observed countries requires further investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a carcinoma | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a lung neoplasms | |
| 650 | 4 | |a non-small-cell Lung | |
| 650 | 4 | |a protein-tyrosine kinases | |
| 650 | 4 | |a retrospective studies | |
| 650 | 4 | |a treatment outcome | |
| 700 | 1 | |a Ramagopalan, Sreeram |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Winson Y |e verfasserin |4 aut | |
| 700 | 1 | |a Wilke, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Alind |e verfasserin |4 aut | |
| 700 | 1 | |a O'Sullivan, Dylan E |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Brenner, Darren R |e verfasserin |4 aut | |
| 700 | 1 | |a Froelich, Carolin |e verfasserin |4 aut | |
| 700 | 1 | |a Inskip, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Maywald, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 130(2024), 4 vom: 15. Feb., Seite 530-540 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g number:4 |g day:15 |g month:02 |g pages:530-540 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.35094 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |e 4 |b 15 |c 02 |h 530-540 | ||